Joo-hang H. Kim
Songnam, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 133 publications
Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.
Journal: Nature medicine
Published: June 29, 2026
Atezolizumab and bevacizumab plus chemotherapy versus chemotherapy in non-small cell lung cancer after tyrosine kinase inhibitor failure.
Journal: Therapeutic advances in medical oncology
Published: December 04, 2025
Durvalumab-containing treatment for recurrent or metastatic pulmonary sarcomatoid carcinoma: A pooled post hoc analysis of two KCSG phase II trials.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 29, 2025
Central Nervous System Outcomes of Lazertinib Treatment in EGFR-Mutated Advanced NSCLC: Pooled Analysis From LASER201 and LASER301.
Journal: Clinical lung cancer
Published: May 30, 2025
A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 24, 2024
Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study.
Journal: BMC medicine
Published: January 17, 2024
Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 07, 2023
Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: July 17, 2023
Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: June 16, 2023
Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.
Journal: Cancer research and treatment
Published: March 09, 2023
Last Updated: 09/26/2026